A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
A phase 1/2 trial of Pembrolizumab in melanoma and uveal melanoma, run by Ascentage Pharma Group Inc., active and no longer recruiting.
Overview
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03611868 by Ascentage Pharma Group Inc., with 230 participants planned, started 2018-08-29 and due to reach its primary completion in 2025-12-30. Interventions recorded: Phase 1b: APG-115+pembrolizumab. Conditions listed: Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Shares Uveal melanoma, Melanoma, Pembrolizumab.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.
- TrialDual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
Shares Uveal melanoma, Melanoma.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Uveal melanoma, Melanoma.
- Trial(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Shares Uveal melanoma, Melanoma.
- TrialAn Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
Shares Uveal melanoma, Melanoma.